Helena Yu

Helena Yu is a leading expert on atypical EGFR mutations in NSCLC, particularly exon 20 insertion mutations that were historically resistant to standard EGFR inhibitors. She has been instrumental in characterizing the clinical activity of amivantamab and mobocertinib in this previously difficult-to-treat population. Her research encompasses the molecular biology of insertion mutations and strategies to improve targeted therapy outcomes. She actively participates in multi-institutional consortia studying rare EGFR variants.